NCT02866136View on ClinicalTrials.gov

Conservative Treatments of Retinoblastoma

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

133

Participants

Timeline

Start Date

February 29, 2012

Primary Completion Date

January 31, 2023

Study Completion Date

September 30, 2035

Conditions
RetinoblastomaChildrenRetinal Neoplasm
Interventions
DRUG

VP16, carboplatin

Systemic treatment : Intravenous injections, 2 cycles (21 days)

DRUG

Melphalan

intraarterial injections, 3 to 6 cycles (1 month)

DRUG

VP16, carboplatin, vincristin

Systemic treatment : Intravenous injections, 6 cycles (21 days)

DRUG

Carboplatin + laser day 1 (chemothermotherapy)

Chemothermotherapy : Intravenous injection by carboplatin and Laser at day 1

DEVICE

Laser (local treatment)

DEVICE

cryoapplication (local treatment)

RADIATION

I125 radioactive plaques (local treatment)

DRUG

intravitreal Melphalan (local treatment)

Trial Locations (1)

75005

Institut Curie, Paris

All Listed Sponsors
collaborator

Fondation Rothschild Paris

OTHER

lead

Institut Curie

OTHER